These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29866866)

  • 1.
    Abdelraouf K; Kim A; Krause KM; Nicolau DP
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
    Rodríguez-Avial I; Pena I; Picazo JJ; Rodríguez-Avial C; Culebras E
    Int J Antimicrob Agents; 2015 Dec; 46(6):616-21. PubMed ID: 26391381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plazomicin activity against polymyxin-resistant Enterobacteriaceae, including MCR-1-producing isolates.
    Denervaud-Tendon V; Poirel L; Connolly LE; Krause KM; Nordmann P
    J Antimicrob Chemother; 2017 Oct; 72(10):2787-2791. PubMed ID: 29091226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial activity of plazomicin against Enterobacteriaceae-producing carbapenemases from 50 Brazilian medical centers.
    Martins AF; Bail L; Ito CAS; da Silva Nogueira K; Dalmolin TV; Martins AS; Rocha JLL; Serio AW; Tuon FF
    Diagn Microbiol Infect Dis; 2018 Mar; 90(3):228-232. PubMed ID: 29223516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms.
    Castanheira M; Deshpande LM; Woosley LN; Serio AW; Krause KM; Flamm RK
    J Antimicrob Chemother; 2018 Dec; 73(12):3346-3354. PubMed ID: 30219857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of plazomicin in combination with other antibiotics against multidrug-resistant Enterobacteriaceae.
    Thwaites M; Hall D; Stoneburner A; Shinabarger D; Serio AW; Krause KM; Marra A; Pillar C
    Diagn Microbiol Infect Dis; 2018 Dec; 92(4):338-345. PubMed ID: 30097297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-Daily Plazomicin for Complicated Urinary Tract Infections.
    Wagenlehner FME; Cloutier DJ; Komirenko AS; Cebrik DS; Krause KM; Keepers TR; Connolly LE; Miller LG; Friedland I; Dwyer JP;
    N Engl J Med; 2019 Feb; 380(8):729-740. PubMed ID: 30786187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections.
    Eljaaly K; Alharbi A; Alshehri S; Ortwine JK; Pogue JM
    Drugs; 2019 Feb; 79(3):243-269. PubMed ID: 30723876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Plazomicin, Tigecycline, and Meropenem Pharmacodynamic Exposure against Carbapenem-Resistant Enterobacteriaceae in Patients with Bloodstream Infection or Hospital-Acquired/Ventilator-Associated Pneumonia from the CARE Study (ACHN-490-007).
    Kuti JL; Kim A; Cloutier DJ; Nicolau DP
    Infect Dis Ther; 2019 Sep; 8(3):383-396. PubMed ID: 31254273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of plazomicin against β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE).
    Zhang Y; Kashikar A; Bush K
    J Antimicrob Chemother; 2017 Oct; 72(10):2792-2795. PubMed ID: 29091224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of plazomicin against quinolone-resistant gram-negative bacteria isolated from catheter-associated urinary tract infections.
    Abd-Elmonsef MME; Nagla S; Afandy ME; Maxwell SY
    J Chemother; 2021 Nov; 33(7):462-468. PubMed ID: 33810779
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Castanheira M; Davis AP; Mendes RE; Serio AW; Krause KM; Flamm RK
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vitro Activity of Plazomicin Against Carbapenem Resistant Klebsiella pneumoniae Strains.
    Demirbas Z; Ozger HS; Suzuk-Yildiz S; Bakkaloglu Z; Dizbay M
    Clin Lab; 2022 Jun; 68(6):. PubMed ID: 35704736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics of plazomicin and a comparator aminoglycoside, amikacin, studied in an in vitro pharmacokinetic model of infection.
    Noel AR; Attwood M; Bowker KE; Kim A; Krause KM; MacGowan AP
    Int J Antimicrob Agents; 2019 Nov; 54(5):626-632. PubMed ID: 31299297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of Plazomicin Tested against
    Castanheira M; Sader HS; Mendes RE; Jones RN
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of Plazomicin against Enterobacteriaceae isolates carrying genes encoding aminoglycoside-modifying enzymes most common in US Census divisions.
    Castanheira M; Davis AP; Serio AW; Krause KM; Mendes RE
    Diagn Microbiol Infect Dis; 2019 May; 94(1):73-77. PubMed ID: 30661726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro activity of several antimicrobial agents against methicillin-resistant Staphylococcus aureus (MRSA) isolates expressing aminoglycoside-modifying enzymes: potency of plazomicin alone and in combination with other agents.
    López Díaz MC; Ríos E; Rodríguez-Avial I; Simaluiza RJ; Picazo JJ; Culebras E
    Int J Antimicrob Agents; 2017 Aug; 50(2):191-196. PubMed ID: 28577932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plazomicin: A Next-Generation Aminoglycoside.
    Shaeer KM; Zmarlicka MT; Chahine EB; Piccicacco N; Cho JC
    Pharmacotherapy; 2019 Jan; 39(1):77-93. PubMed ID: 30511766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of plazomicin compared to other clinically relevant aminoglycosides in carbapenem-resistant Enterobacteriaceae.
    Clark JA; Kulengowski B; Burgess DS
    Diagn Microbiol Infect Dis; 2020 Oct; 98(2):115117. PubMed ID: 32755805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective Observational Study from a Chinese Network of the Impact of Combination Therapy versus Monotherapy on Mortality from Carbapenem-Resistant
    Wang X; Wang Q; Cao B; Sun S; Zhang Y; Gu B; Li B; Liao K; Zhao F; Jin L; Jin C; Yang C; Pei F; Zhang Z; Wang H
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30348660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.